Catalyst Wire Dossier Catalyst Wire Dossier

Natalizumab

natalizumab · Biogen
Drug timelines are a Plus or Pro feature.

32 regulatory and trial events tracked for Natalizumab, covering 2008-01-25 to 2026-04-08. Get the full timeline:

Most recent: Clinical Trial Update: A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

See pricing